Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

15 Dec 2021 15:00

RNS Number : 7755V
AstraZeneca PLC
15 December 2021
 

15 December 2021 15:00 GMT

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announces that Tony Mok, a Non-Executive Director of the Company, purchased 2,000 of the Company's American Depositary Shares (ADSs) on 13 December 2021. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.

 

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Tony Mok

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

AstraZeneca PLC American Depositary Shares

 

 

CUSIP: 046353108

b)

 

Nature of the transaction

 

 

Purchase of AstraZeneca PLC American Depositary Shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

US$54.29

2,000

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

13 December 2021

f)

 

Place of the transaction

 

XNAS

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUVOORAOUUAAA
Date   Source Headline
6th Mar 20177:00 amRNSDirectorate Change
3rd Mar 20177:00 amRNSALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
1st Mar 20174:30 pmRNSTotal Voting Rights
28th Feb 20177:02 amRNSFDA approves once-daily Qtern for type-2 diabetes
24th Feb 201712:32 pmRNSCHMP positive opinion for ZS-9 in hyperkalaemia
20th Feb 20177:00 amRNSAZ licenses Zoladex to TerSera for the US & Canada
17th Feb 20177:00 amRNSLynparza positive in metastatic BRCA breast cancer
16th Feb 201712:01 pmRNSSILIQ (BRODALUMAB) APPROVED BY US FDA
2nd Feb 20177:00 amRNSAZN: FY16 and Q4 2016 Results
1st Feb 20174:00 pmRNSTotal Voting Rights
26th Jan 201710:00 amRNSSYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17th Jan 20177:00 amRNSAZ 1st-line lung cancer immuno-oncology programme
3rd Jan 20174:00 pmRNSTotal Voting Rights
23rd Dec 20167:00 amRNSAZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16th Dec 20161:00 pmRNSDirector/PDMR Shareholding
9th Dec 20163:05 pmRNSFDA accepts durvalumab for BLA in bladder cancer
6th Dec 20169:30 amRNSTagrisso data shows superiority over chemotherapy
5th Dec 20167:00 amRNSAZ completes agreement for Rhinocort Aqua rights
1st Dec 20164:00 pmRNSBlock listing Interim Review
1st Dec 20163:00 pmRNSTotal Voting Rights
22nd Nov 20167:00 amRNSAZ head and neck cancer trials resume enrolment
17th Nov 20167:00 amRNSAZ out-licensing deal with Allergan completed
10th Nov 20167:04 amRNSYear-To-Date and Q3 2016 Results
9th Nov 20167:00 amRNSDirectorate Change
1st Nov 20163:30 pmRNSDealing by Person Closely Associated
1st Nov 20163:00 pmRNSTotal Voting Rights
31st Oct 20161:47 pmRNSAZ completes US Aralez agreement for Toprol-XL
27th Oct 20164:51 pmRNSAstraZeneca Head and Neck Cancer Trials
26th Oct 20167:00 amRNSPositive results in AstraZeneca Lynparza trial
18th Oct 20167:00 amRNSFDA accepts for review ZS-9 NDA for hyperkalaemia
7th Oct 20167:00 amRNSAZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
4th Oct 20167:05 amRNSAZ agreement with Aralez for Toprol-XL in US
4th Oct 20167:00 amRNSAstraZeneca reports top-line EUCLID results in PAD
3rd Oct 20163:00 pmRNSTotal Voting Rights
3rd Oct 20167:00 amRNSMedImmune out-licenses medicine to Allergan
28th Sep 20167:00 amRNSCHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26th Sep 20164:00 pmRNSDirector/PDMR Shareholding
22nd Sep 201611:00 amRNSDirector Declaration
1st Sep 20162:30 pmRNSTotal Voting Rights
1st Sep 20167:00 amRNSAstraZeneca Completes Aspen Agreement
24th Aug 20167:00 amRNSAZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18th Aug 20161:00 pmRNSDirector Declaration
16th Aug 20167:00 amRNSAstraZeneca completes agreement with LEO Pharma
10th Aug 20162:41 pmRNSASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
9th Aug 20167:00 amRNSASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
1st Aug 20162:30 pmRNSTotal Voting Rights
1st Aug 201611:00 amRNSDirector/PDMR Shareholding
28th Jul 20167:00 amRNSAZN: H1 2016 Results
27th Jul 20169:00 amRNSNotice of Results
19th Jul 20162:15 pmRNSQTERN (saxa/dapa) EU approved for type-2 diabetes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.